Trial Profile
Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish and Danish Medical Birth Registers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Inflammatory bowel diseases; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Centocor; Janssen Biotech
- 01 Sep 2017 Status changed from active, no longer recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.